Navigation Links
Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
Date:11/21/2007

Targeting tumor's vulnerability yields durable responses in Phase I/II

Trial

SEATTLE, Nov. 21 /PRNewswire-FirstCall/ -- Systems Medicine, LLC (SM), a wholly-owned subsidiary of Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX), announced that cumulative preliminary results of a phase I trial combining cisplatin with brostallicin in patients with solid tumors that had relapsed or were resistant to front-line treatment were presented at the Highlights in Oncology meeting in Naples, Italy, on Tuesday, November 20, 2007. Cristina Geroni, Ph.D. of Nerviano Medical Sciences (NMS), which developed brostallicin, summarized the basis for the phase I trial design. The trial is based on data demonstrating tumors with high levels of GSH/GST, common in platinum-resistant disease, are more susceptible to the killing effects of brostallicin. High levels of GSH and GST are associated with resistance to most standard chemotherapy drugs

"Our phase I and II experience with brostallicin in over 160 patients demonstrates encouraging anti-tumor activity in a variety of solid tumors, with more than 50% of the patients experiencing at least disease stabilization," said Steven Weitman, M.D., of Systems Medicine.

The preliminary results from the first 21 patients treated in the phase I combination trial with cisplatin showed similar results, with 14 of the patients experiencing stable disease and half (50%) of those 14 patients having durable stable disease for more than six cycles of therapy. Toxicities were mainly hematological and were manageable and reversible in this heavily pretreated patient population. Phase II studies using this combination in patients resistant to standard therapy are planned.

About the Phase I Study

The phase I, multicenter, dose-escalation study of brostallicin in combination with cisplatin (cDDP) was conducted in patients with recurrent or metastatic solid tumors. Treatment cycles wer
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Phase III Trial Finds Pharmaxis Bronchitol Effective
9. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
10. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013 The new Public-Private Partnership (PPP) ... the association’s recent annual meeting drew praise from community ... Kroes, who called the action “a huge step forward ... to European innovation.” , The Board of Stakeholders voted ... Photonics PPP at its 29 April meeting in Brussels, ...
(Date:5/17/2013)... -- New interactive learning forums will ... of the medical device industry at the 2013 ... from June 18-20 in Philadelphia ... ) , These all-new MedTech Innovate ... presentations and implementable solutions on the most cutting-edge ...
(Date:5/17/2013)... BEIJING , May 17, 2013  Yongye International, ... "Company"), a leading developer, manufacturer, and distributor of crop ... China , today announced that, on May 16, ... board of directors (the "Board of Directors") was provided ... ( Hong Kong ) Limited ("Abax") to ...
(Date:5/17/2013)... Health, Inc., a company developing natural compounds to address ... is today reporting top-line results from a Phase Ib ... drug-resistant epilepsy.  The data are being presented at the ... Dr. Steven Schachter , Harvard Medical ... In this study, INS001 appeared safe and well tolerated. ...
Breaking Biology Technology:SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Yongye International Provides Update on Status of Proposed Go Private Offer 2Yongye International Provides Update on Status of Proposed Go Private Offer 3Yongye International Provides Update on Status of Proposed Go Private Offer 4Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2
... LUND, Sweden, January 18 ,ThromboGenics NV (Euronext ... (Nordic Exchange: BINV) announce today that they,have ... Denmark to,initiate a Phase I clinical trial ... a monoclonal antibody that targets the angiogenic ...
... CLAREMONT, Calif., Jan. 17 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech ... annual,management meetings including yearend business review, planning ... commenced in,Xiaotangshan, Beijing on January 11, 2008., ... staff from Kiwa,s corporate,headquarters in Beijing, and ...
... Types Broadens Project Coalition with Addition of ... Misys Healthcare, CHICAGO, Jan. 17 The HL7 ... starts 2008 on a strong,note adding four new benefactors ... Systems joined in the fall of 2007,ImageTek, Inc. in ...
Cached Biology Technology:ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer 2ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer 3ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer 4ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer 5Kiwa Holds 2007 Annual Management Meetings and Employee Recognition Ceremonies in Beijing 2Kiwa Holds 2007 Annual Management Meetings and Employee Recognition Ceremonies in Beijing 3New Benefactors Show Support for CDA4CDT: 2New Benefactors Show Support for CDA4CDT: 3New Benefactors Show Support for CDA4CDT: 4New Benefactors Show Support for CDA4CDT: 5New Benefactors Show Support for CDA4CDT: 6New Benefactors Show Support for CDA4CDT: 7
(Date:5/17/2013)... the white noise of the South, but the night belongs ... air hangs heavy from the humidity and the sounds of ... species of frogs, toads and salamanders, is the center of ... swamps are the auditorium for their symphonic choruses, the scientists ... or ARMI, have front-row seats. , Amphibians, which ...
(Date:5/17/2013)... Why Tibetan antelope can live at elevations of ... research published in Nature Communications , investigators ... evidence that some genetic factors may be associated ... The data in this work will also provide ... biology of other ruminant species. , The Tibetan ...
(Date:5/17/2013)... team of scientists using a new X-ray method recorded ... frog embryo in greater detail than ever before., This ... and the search for new treatments for genetic diseases., ... Technologie in Germany, in collaboration with the Advanced Photon ... Laboratory, released the most precise depiction ever of the ...
Breaking Biology News(10 mins):Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4The genome sequence of Tibetan antelope sheds new light on high-altitude adaptation 2New X-ray method shows how frog embryos could help thwart disease 2
... scientist, explorer and conservationist, will receive the Academy of ... He is the first Australian to receive the award ... leading thinkers and writers, Flannery has discovered more than ... has published more than 130 peer-reviewed scientific papers and ...
... that a certain class of RNA (known as long non-protein-coding ... infection. These findings, published today in the online journal ... at the body,s response to viral infection. "To our ... technology to clearly demonstrate that lncRNAs are involved in the ...
... Ohio New research links three molecules to a critical ... myeloma, a presently incurable cancer of the blood. , The ... and other blood cancers, according to researchers at The Ohio ... Richard J. Solove Research Institute (OSUCCC James) who led ...
Cached Biology News:Scientist Tim Flannery is first Austrailian to receive Joseph Leidy Award 2A new player in the innate immunity game? 2Study identifies key molecules in multiple myeloma 2
Microlite 1+ 1x12 Strip assembled, flat bottom; the ideal vessel for low signal luminescent reactions, offering medium binding with enhanced dynamic range, extra high reflectivity and minimal cross t...
... HERAfreeze ultra low temperature freezers offer ... safe storage of biological samples with ... five separate inner doors ensure excellent ... costs. ,Application oriented accessories simplify ...
...
...
Biology Products: